Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.56 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20812313 | 0.90 | CRBN (0.64) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL283113 | 0.84 | CRBN (0.74) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24269131 | 0.84 | CRBN (0.53) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL22158629 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL30899477 | 0.79 | CRBN (0.56) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL20812183 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL23267776 | 0.79 | CRBN (0.72) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL24267061 | 0.78 | CRBN (0.43) | CRBNDDB1GSPT1 | |
| SCHEMBL20772973 | 0.77 | CRBN (0.60) | CRBNDDB1IKZF3 | |
| SCHEMBL20811949 | 0.77 | CRBN (0.83) | CRBNDDB1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | CRBN 4/4885DDB1 263/4885IKZF3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.